Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

Fresenius Kabi USA, LLC

US Class II Ongoing · initiated 2026-03-11

Lack of Assurance of Sterility

VENLAFAXINE XR 75mg

Canada Type II Ongoing · initiated 2026-03-10

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health conce…

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2026-03-09

Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.

KETOROLAC

Canada Type II Ongoing · initiated 2026-03-09

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health conce…

PAYLESS COMPOUNDERS, LLC

US Class II Ongoing · initiated 2026-03-06

Lack of Assurance of Sterility

Apotex Corp.

US Class II Ongoing · initiated 2026-03-05

Lack of Assurance of Sterility

APO-BRIMONIDINE-TIMOP

Canada Type II Ongoing · initiated 2026-03-05

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product, or for any health concer…

Rising Pharma Holding, Inc.

US Class II Ongoing · initiated 2026-03-03

Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing

K.C. Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-03-03

Lack of Assurance of Sterility

K.C. Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-03-03

Lack of Assurance of Sterility

K.C. Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-03-03

Lack of Assurance of Sterility

K.C. Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-03-03

Lack of Assurance of Sterility

K.C. Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-03-03

Lack of Assurance of Sterility

K.C. Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-03-03

Lack of Assurance of Sterility

K.C. Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-03-03

Lack of Assurance of Sterility

K.C. Pharmaceuticals, Inc

US Class II Ongoing · initiated 2026-03-03

Lack of Assurance of Sterility

Owen Biosciences Inc.

US Class II Ongoing · initiated 2026-03-03

Chemical contamination: Presence of benzene

Owen Biosciences Inc.

US Class II Ongoing · initiated 2026-03-03

Chemical contamination: Presence of benzene

Owen Biosciences Inc.

US Class II Ongoing · initiated 2026-03-03

Chemical contamination: Presence of benzene

Owen Biosciences Inc.

US Class II Ongoing · initiated 2026-03-03

Chemical contamination: Presence of benzene

STRIDES PHARMA INC

US Class II Ongoing · initiated 2026-03-02

Presence of foreign substance: the firm received complaints for a gel-like mass and black particles in the product.